

CITATION REPORT

List of articles citing

Transition of PH patients from sildenafil to tadalafil:
feasibility and practical considerations

DOI: 10.1007/s00408-012-9408-6

Lung, 2012, 190, 573-8.

Source: <https://exaly.com/paper-pdf/53210240/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
13	Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension. <i>Cardiovascular Therapeutics</i> , 2013 , 31, 274-9	3.3	10
12	Daily dosing of PDE5 inhibitors: where does it fit in?. <i>Current Urology Reports</i> , 2013 , 14, 269-78	2.9	5
11	Management of pulmonary arterial hypertension. <i>Current Opinion in Critical Care</i> , 2013 , 19, 44-50	3.5	7
10	Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014 , 19, 550-7	2.6	10
9	Contribution of CYP3A isoforms to dealkylation of PDE5 inhibitors: a comparison between sildenafil N-demethylation and tadalafil demethylation. <i>Biological and Pharmaceutical Bulletin</i> , 2015 , 38, 58-65	2.3	13
8	Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review. <i>Core Evidence</i> , 2015 , 10, 99-109	4.9	19
7	Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension. <i>Lung</i> , 2015 , 193, 105-12	2.9	18
6	Oral Tadalafil in Children with Pulmonary Arterial Hypertension. <i>Drug Research</i> , 2016 , 66, 7-10	1.8	14
5	A systematic review of transition studies of pulmonary arterial hypertension specific medications. <i>Pulmonary Circulation</i> , 2017 , 7, 326-338	2.7	19
4	In Vitro P-Glycoprotein-Mediated Transport of Tadalafil: A Comparison with Sildenafil. <i>Biological and Pharmaceutical Bulletin</i> , 2017 , 40, 1314-1319	2.3	1
3	Successful Transition From Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study. <i>Heart Lung and Circulation</i> , 2020 , 29, 331-336	1.8	6
2	Transition from Bosentan to Ambrisentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study. <i>International Journal of General Medicine</i> , 2021 , 14, 2101-2107	2.3	1
1	The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-world Prospective Study.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 811700	5.6	0